These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 19191677)

  • 1. Tuberculosis pharmacotherapy: strategies to optimize patient care.
    Mitnick CD; McGee B; Peloquin CA
    Expert Opin Pharmacother; 2009 Feb; 10(3):381-401. PubMed ID: 19191677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs and regimens for treatment of TB.
    Leibert E; Rom WN
    Expert Rev Anti Infect Ther; 2010 Jul; 8(7):801-13. PubMed ID: 20586565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifamycins--obstacles and opportunities.
    Aristoff PA; Garcia GA; Kirchhoff PD; Showalter HD
    Tuberculosis (Edinb); 2010 Mar; 90(2):94-118. PubMed ID: 20236863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antituberculous drugs in development.
    Lalloo UG; Ambaram A
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):143-51. PubMed ID: 20559756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-resistant tuberculosis: what are the treatment options?
    Albanna AS; Menzies D
    Drugs; 2011 May; 71(7):815-25. PubMed ID: 21568360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
    Regazzi M; Carvalho AC; Villani P; Matteelli A
    Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current development and future prospects in chemotherapy of tuberculosis.
    Nuermberger EL; Spigelman MK; Yew WW
    Respirology; 2010 Jul; 15(5):764-78. PubMed ID: 20546189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolones and tuberculosis.
    Bryskier A; Lowther J
    Expert Opin Investig Drugs; 2002 Feb; 11(2):233-58. PubMed ID: 11829714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.